Back

The effect of omecamtiv mecarbil on outcomes analysed using the win ratio: an exploratory analysis of GALACTIC-HF

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Clinical trials updates in medical therapy Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Kieran Docherty

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Discussant panel
Presentation thumbnail
Effects of finerenone on readmissions for heart failure: a prespecified secondary analysis of the FINEARTS-HF trial
Doctor A. Bhatt (San Francisco, US)
Slides Video
Presentation thumbnail
Trade-off of risk and benefit of finerenone across the spectrum of kidney function in patients with heart failure with mildly reduced and preserved ejection fraction in the FINEARTS-HF trial
Doctor S. Chatur (Boston, US)
Slides Video
Presentation thumbnail
Intravenous ferric carboxymaltose in heart failure with iron deficiency
Doctor M. Karakas (Hamburg, DE)
Slides Video
Presentation thumbnail
Efficacy of intravenous iron for the treatment of heart failure varies by method of meta-analysis: a Bayesian and frequentist reappraisal of the evidence
Doctor A. Henderson (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
Clinical trials updates in medical therapy
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Omecamtiv mecarbil
thumbnail
Congress Presentation
Analysis of the PARAGON-HF study results using win ratio
thumbnail
Congress Presentation
The totality of evidence for a new pillar in HFrEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources